FDA Awards Accelerated Approval to Gilead Sciences Drug for Rare Liver Disease
Posted
Frank Vinluan (via MedCity News)
Livdelzi is now FDA-approved for treating the rare liver disease primary biliary cholangitis. Gilead Sciences added the drug to its pipeline via the $4.3 billion acquisition of CymaBay Therapeutics earlier this year.
The post FDA Awards Accelerated Approval to Gilead Sciences Drug for Rare Liver Disease appeared first on MedCity News.
